FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
--	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burd	en								
hours per response:	0.5								

1. Name and Address of Reporting Person [*] KAZIMI A J			2. Issuer Name and Ticker or Trading Symbol CUMBERLAND PHARMACEUTICALS	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
			INC [CPIX]	X	Director	Х	10% Owner		
(Last) (First) (Middle)		(Middle)		x	Officer (give title below)		Other (specify below)		
2525 WEST END AVE. SUITE 950			3. Date of Earliest Transaction (Month/Day/Year) 04/01/2010		Chairman and CEO				
<u>,</u>			4. If Amendment, Date of Original Filed (Month/Day/Year)		ridual or Joint/Group F	iling (Check Applicable		
(Street) NASHVILLE	TN	37203		Line) X	Form filed by One F Form filed by More	•	0		
(City)	(State)	(Zip)			Person				

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)			4. Securities A Disposed Of (5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1130.4)	
Common stock	04/01/2010		S		9,479 ⁽¹⁾	D	\$10.55	5,425,345	D		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

	*									3					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Nu of Deriv Secu Acqu (A) or Dispo of (D) (Instr and 5	Expiration Date (Month/Day/Year) irrites irred osed) (, 3, 4		te Amount of			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(S) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. Represents the repurchase of shares by the Company to settle the tax liability associated with the option transaction discussed on page 99 of the Company's prospectus filed pursuant to Rule 424(b)(4) with the SEC on August 12, 2009.

Remarks:

<u>A.J. Kazimi by: /s/ David L.</u>

04/01/2010

Lowrance as attorney-in-fact ** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Date